Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 21:10:25 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Episurf Medical - 21’Q4 Review – US on the horizon

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Episurf Medical - 21’Q4 Review – US on the horizon

2022-02-15 10:00:00

Redeye argues that the lower-than-anticipated sales do not reflect the long-term case of Episurf and that its potential US market entry by H2 this year will be an important milestone for the company. We expect a slower market ramp-up than previously and adjust our estimates, which are now including the Patellofemoral system. Our Fair Value remains intact.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/